Rapamycin ≥98%, Pulver

Lieferant: ICN Biomedicals

ICNA0215934680EA 70.2 CHF
ICNA0215934680 ICNA0215934691
Rapamycin ≥98%, Pulver
Rapamycin

Rapamycin binds to and inhibits the molecular target of rapamycin (mTOR). It forms a complex with FKBP12 that binds to and inhibits the molecular target of rapamycin (mTOR). Rapamycin is a potent immunosuppressant and has anticancer activity.


Rapamycin is unique in its ability to inhibit lymphokine induced cell proliferation at the G1 and S phase as well as an irreversible cellular arrest at the G1 phase in S. cerevisiae cells. It also exhibits selective signal blocking leading to the activation of p70/85 S6 kinase, which is potentially due to the inhibition of FRAP autophosphorylation or protein kinase activity. Angiogenesis inhibition is also exhibited, possibly through the inhibition of the Akt pathway. Induces autophagy in yeast and mammalian cell lines.


Soluble in ether, chloroform, acetone, DMF, methanol (25 mg/ml - clear, colorless solution) or DMSO; very sparingly soluble in hexane and petr ether; insoluble in water.

Formel: C₅₁H₇₉NO₁₃
MW: 914,19 g/mol
MDL Number: MFCD00867594
CAS-Nummer: 53123-88-9

Order Now

Learn more

About VWR

Avantor is a vertically integrated, global supplier of discovery-to-delivery solutions for...

Mehr About VWR